Search for Clinical Trial Results

Sponsored By

Mantle Cell Lymphoma - 27 Studies Found

Status Study
Completed Study Name: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Condition: Mantle Cell Lymphoma
Date: 2025-11-04
Interventions: Given by PO
COMPLETED Study Name: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2025-11-04
Interventions: The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for do
COMPLETED Study Name: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2025-11-04
Interventions: Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food,
COMPLETED Study Name: Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial
Condition: Recurrent Mantle Cell Lymphoma
Date: 2025-11-04
Interventions: Undergo blood, saliva or tissue sample collection
COMPLETED Study Name: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2025-11-04
Interventions: Bendamustine will be administered at a dose of 90 mg/m^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
COMPLETED Study Name: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
Condition: Relapsed/Refractory Mantle Cell Lymphoma
Date: 2025-11-04
Interventions: Administered intravenously
COMPLETED Study Name: The Role of 18F-FDG-PET for Staging and Prognostication
Condition: Mantle Cell Lymphoma
Date: 2025-11-04
<<< Previous